Central nervous system metastases in women who receive trastuzumab‐based therapy for metastatic breast carcinoma

By J. Bendell, S. Domchek, H. Burstein, L. Harris, J. Younger, I. Kuter, C. Bunnell, M. Rue, R. Gelman, E. Winer. Cancer, 2003

722 citations recorded by the source corpus.

Subfields: Oncology, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/735a1155d2626c50c0e74d887812c7cf47cda5cb

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Oncology

1. D. Hanahan
2. G. Bergers
3. P. Steeg
4. R. Weinberg
5. Rakesh K. Jain
6. Lisa M. Coussens

In Pulmonary and Respiratory Medicine

1. D. Hanahan
2. P. Steeg

Citations in the corpus

• Tumor metastasis: mechanistic insights and clinical challenges (2006, background): “For people with metastatic breast cancer whose tumors overexpress Her-2 and are treated with trastuzumab, the incidence of brain metastases may be twice that of other breast cancer patients and often occurred when the patients were responding to therapy at other sites or had stable diseas”
• Heterogeneous Blood-Tumor Barrier Permeability Determines Drug Efficacy in Experimental Brain Metastases of Breast Cancer (2010, neutral): “The net effect is that the patient experience is changing (6), with brain metastases more commonly presenting in patients who are responding to systemic therapy or have stable disease, and patients are succumbing to brain metastases (7).”
• Brain metastases: epidemiology and pathophysiology (2005, background): “If, as more recent data indicate, the incidence of brain metastasis is increasing, as treatment of the non-CNS tumors improves [13, 14], the true incidence may be even higher.”
• Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. (2009, background): “Although effective in its antitumor and prosurvival effects (13 months increased life span), trastuzumab therapy changes the course of disease progression in these patients to one with a markedly increased incidence of brain metastasis (Bendell et al., 2003; Clayton et al., 2004; Miller et al., 2003”
• Multicenter Phase II Study of Lapatinib in Patients with Brain Metastases from HER2-Positive Breast Cancer (2009, background): “5 (29-77) 49 (27-87) 49 (27-87) Race African American/African 3 (3) 4 (3) 7 (3) Asian 8 (8) 9 (6) 17 (6) White: White/Caucasian/European 83 (88) 129 (88) 212 (88) Disease status Median time since first diagnosis of metastatic disease, d (range) 716 (102-3,796) 952 (79-4,452) 855 (79-4,452) Disease s”